Used in Clinical Haematology, DAWN High Risk Medication Monitoring Software, empowers nurse-led clinics to safely and efficiently manage MGUS or MPD patients. Our software supports protocol-driven monitoring, enables the easy identification of patients with abnormal or missing test results, provides dosing and scheduling tools and prioritises ...

DAWN Clinical Haematology software empowers nurse-led clinics to manage patients with long term conditions such as MGUS or MPD safely and efficiently. It supports protocol-driven monitoring, enables the easy identification of patients with abnormal or missing test results, provides dosing and scheduling tools and prioritises actions requiring ...

2025年2月17日 · Intermediate- and high-risk MGUS should trigger bone marrow biopsy and bone imaging to detect overt MM and shorter monitoring intervals. Advanced molecular testing may improve on current risk stratification to target monitoring and treatment to those with highest risk of malignant progression and avoid overtreatment of those with low-risk disease.

2018年1月11日 · Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

2024年12月6日 · Focusing on the neurological manifestations of MGUS affecting the peripheral nervous system, we describe 3 illustrative cases from daily practice and discuss different aspects of diagnosis to treatment, emphasizing the need for multidisciplinary management based on the close collaboration of neurologists and hematologists.

MGUS is a condition in which abnormal plasma cells produce too much M protein in the blood. It is often found during routine blood tests. It is not. cancer. When MGUS turns into myeloma, the excess amount of M protein can lead to damage of the organs and decrease the body’s ability to …

意义未明单克隆免疫球蛋白血症（MGUS）是指血中存在单克隆免疫球蛋白（M蛋白<3g/dl），尿中少量或无M蛋白，骨髓浆细胞比例小于10%，无终末脏器损伤的一类良性疾病。

2023年5月19日 · This Good Practice Paper provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed.

Monoclonal gammopathy of undetermined significance (MGUS) is one of the most common pre-malignant conditions in western countries with a prevalence of 3.2% in the Caucasian general population 50 years of age or older. 1 It is characterized by the presence of a monoclonal immunoglobulin (Ig) (M-protein) in individuals lacking evidence of ...

This clinic uses a computer programme called “DAWN” to ensure that your blood results are reviewed by your healthcare team. You will need to have blood tests every six or twelve months. We will write to you with the results and the date of your next appointment. We will send you forms for your next blood tests.